Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.315ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.315SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.516ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.516SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.354ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.354SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.162ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.162SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.426ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.426SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.402ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.402SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.424ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.424SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.61ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.61SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.264ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.264SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.581ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.581SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.330ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.330SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.205ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.205SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.177ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.177SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.301ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.301SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.308ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.308SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.210ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.210SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.1.325ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.1.325SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.590ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.590SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.116ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.116SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.496ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.496SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
B.1.438.4ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.438.4SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
AY.49 (Delta)ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.595.4ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.495ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.294ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.1.453ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.44ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.350ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.304ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used